These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 35607886

  • 1. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients.
    Salerno SN, Capparelli EV, McIlleron H, Gerhart JG, Dumond JB, Kashuba ADM, Denti P, Gonzalez D.
    Pharmacotherapy; 2023 Jul; 43(7):638-649. PubMed ID: 35607886
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Brief Report: Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change.
    Jacobs TG, Mumbiro V, Chitsamatanga M, Namuziya N, Passanduca A, Domínguez-Rodríguez S, Tagarro A, Nathoo KJ, Nduna B, Ballesteros A, Madrid L, Mujuru HA, Chabala C, Buck WC, Rojo P, Burger DM, Moraleda C, Colbers A, EMPIRICAL Clinical Trial Group, EMPIRICAL Clinical Trial Group.
    J Acquir Immune Defic Syndr; 2023 May 01; 93(1):42-46. PubMed ID: 36724434
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients.
    Wang K, D'Argenio DZ, Acosta EP, Sheth AN, Delille C, Lennox JL, Kerstner-Wood C, Ofotokun I.
    Clin Pharmacokinet; 2014 Apr 01; 53(4):361-71. PubMed ID: 24311282
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa.
    Chupradit S, Wamalwa DC, Maleche-Obimbo E, Kekitiinwa AR, Mwanga-Amumpaire J, Bukusi EA, Nyandiko WM, Mbuthia JK, Swanson A, DNDi Clinical TeamDrugs for Neglected Diseases Initiative, Geneva, Switzerland.Drugs for Neglected Diseases Initiative, Nairobi, Kenya.Drugs for Neglected Diseases Initiative, Bethesda, Maryland, USA., Cressey TR, Punyawudho B, Musiime V, LIVING Study Team.
    Clin Pharmacol Ther; 2024 May 01; 115(5):1105-1113. PubMed ID: 38247190
    [Abstract] [Full Text] [Related]

  • 13. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA, Hendrix CW, Barditch-Crovo P, Parsons T, Khan W, Parish M, Radebaugh C, Carson KA, Pakes GE, Qaqish R, Flexner C.
    Antivir Ther; 2007 May 01; 12(6):963-9. PubMed ID: 17926651
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
    Kendall MA, Lalloo U, Fletcher CV, Wu X, Podany AT, Cardoso SW, Ive P, Benson CA.
    Clin Infect Dis; 2021 Aug 16; 73(4):706-715. PubMed ID: 34398956
    [Abstract] [Full Text] [Related]

  • 18. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
    Kashuba AD, Tierney C, Downey GF, Acosta EP, Vergis EN, Klingman K, Mellors JW, Eshleman SH, Scott TR, Collier AC.
    AIDS; 2005 Jan 28; 19(2):145-52. PubMed ID: 15668539
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
    Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.
    AIDS; 2005 Apr 29; 19(7):685-94. PubMed ID: 15821394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.